The EWOC-1 trial looked at single-agent carboplatin in vulnerable, elderly patients with stage III/IV epithelial ovarian cancer vs weekly or every 3 weeks carboplatin/paclitaxel.
Data from a phase II study were presented at ASCO 2019, focusing on responses among women with BRCA wild-type ovarian cancer to olaparib.
This FDA confirmatory phase III study evaluated olaparib vs treatment of physician’s choice in BRCA-mutated, platinum-sensitive relapsed ovarian cancer.
Data from the first-in-human study of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, were presented at ASCO 2019.
The phase II AVANOVA trial examined PFS in advanced ovarian cancer patients who received a PARP inhibitor plus bevacizumab.
The survival benefit observed with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia in the ADMIRAL trial was maintained regardless of the presence of several common co-mutations.
The COLUMBA trial examined the efficacy, number of infusion-related reactions, and administration time for SC vs IV daratumumab in R/R multiple myeloma.
Daratumumab + European Standard Yields Clinical Benefit in Transplant Eligible, Newly Diagnosed Myeloma
New data from the CASSIOPEIA trial evaluated the use of daratumumab in addition to bortezomib/thalidomide/dexamethasone after ASCT in multiple myeloma.
A phase III study tested the combination conditioning regimen of busulfan plus melphalan vs standard melphalan alone for patients with newly diagnosed multiple myeloma undergoing transplantation.
Researchers tested whether use of blue dye injection during sentinel lymph node biopsy can be safely omitted prior to Mohs surgery for malignant melanoma.